The generic name for Kisqali is ribociclib [1].
What is ribociclib used for?
Ribociclib is a medication prescribed for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is typically used in combination with an aromatase inhibitor or fulvestrant in postmenopausal women or in men, and in pre-menopausal women in combination with an aromatase inhibitor or tamoxifen [1].
How does ribociclib work?
Ribociclib is a cyclin-dependent kinase (CDK) inhibitor. Specifically, it inhibits CDK4 and CDK6, which are enzymes that play a role in cell growth and division. By blocking these kinases, ribociclib can help slow or stop the growth of cancer cells [2].
When did Kisqali (ribociclib) receive FDA approval?
Kisqali first received FDA approval on April 11, 2017, for use in postmenopausal women with HR+, HER2- advanced or metastatic breast cancer, in combination with an aromatase inhibitor [3]. Subsequent approvals expanded its use to other patient populations and combinations [1].
What are the common side effects of ribociclib?
Common side effects associated with ribociclib treatment include low white blood cell counts (neutropenia), nausea, vomiting, diarrhea, hair loss, fatigue, and abdominal pain [1]. Patients undergoing treatment are monitored for these and other potential adverse effects.
What is the patent status for Kisqali (ribociclib)?
Information regarding the patent status of Kisqali and its generic versions can be found on DrugPatentWatch.com [4]. Patent expiry dates and any associated litigation or challenges can significantly impact the availability of generic alternatives and their pricing.
What are the alternatives to ribociclib for breast cancer treatment?
Other CDK4/6 inhibitors used in combination therapy for HR+, HER2- advanced or metastatic breast cancer include palbociclib (Ibrance) and abemaciclib (Verzenio) [5]. The choice of treatment depends on individual patient factors, cancer characteristics, and prior therapies.